| D009154 |
Mutation |
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. |
Mutations |
|
| D011951 |
Receptors, Complement |
Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement. |
Complement Receptors,Complement Receptor,Complement Receptor Type 1,Receptor, Complement |
|
| D002176 |
Candida albicans |
A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). |
Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans |
|
| D003179 |
Complement C3b |
The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g. |
C3b Complement,C3bi,Complement 3b,Complement Component 3b,Inactivated C3b,iC3b,C3b, Complement,C3b, Inactivated,Complement, C3b,Component 3b, Complement |
|
| D000944 |
Antigens, Differentiation, B-Lymphocyte |
Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin. |
Antigens, Differentiation, B-Cell,B-Cell Differentiation Antigens,B-Lymphocyte Differentiation Antigens,Blast-2 Antigen, B-Cell,Differentiation Antigens, B-Cell,Differentiation Antigens, B-Lymphocyte,Leu Antigens, B-Lymphocyte,Plasma Cell Antigens PC-1,Antigens, Differentiation, B Lymphocyte,Antigens, Plasma Cell, PC-1,B-Cell Blast-2 Antigen,Antigen, B-Cell Blast-2,Antigens, B-Cell Differentiation,Antigens, B-Lymphocyte Differentiation,Antigens, B-Lymphocyte Leu,B Cell Blast 2 Antigen,B Cell Differentiation Antigens,B Lymphocyte Differentiation Antigens,B-Lymphocyte Leu Antigens,Blast 2 Antigen, B Cell,Differentiation Antigens, B Cell,Differentiation Antigens, B Lymphocyte,Leu Antigens, B Lymphocyte,Plasma Cell Antigens PC 1 |
|
| D014774 |
Virulence |
The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS. |
Pathogenicity |
|
| D015151 |
Immunoblotting |
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. |
Dot Immunoblotting,Electroimmunoblotting,Immunoelectroblotting,Reverse Immunoblotting,Immunoblotting, Dot,Immunoblotting, Reverse,Dot Immunoblottings,Electroimmunoblottings,Immunoblottings,Immunoblottings, Dot,Immunoblottings, Reverse,Immunoelectroblottings,Reverse Immunoblottings |
|
| D015933 |
Complement C3d |
A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001). |
C3d Complement,Complement 3d,Complement C3d Fragment,Complement Component 3d,C3d Fragment, Complement,C3d, Complement,Complement, C3d,Component 3d, Complement,Fragment, Complement C3d |
|
| D017463 |
Receptors, Complement 3b |
Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. |
Antigens, CD35,C3b Receptors,CD35 Antigens,CR1 Receptors,Complement 3b Receptors,Receptors, C3b,Receptors, CR1,CD 35 Antigens,CD35 Antigen,Complement 3b Receptor,Antigen, CD35,Antigens, CD 35,Receptor, Complement 3b |
|
| D017464 |
Receptors, Complement 3d |
Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognize and combine with COMPLEMENT C3D. Human complement receptor 2 (CR2) serves as a receptor for both C3dg and the gp350/220 glycoprotein of HERPESVIRUS 4, HUMAN, and binds the monoclonal antibody OKB7, which blocks binding of both ligands to the receptor. |
Antigens, CD21,C3d Receptors,CD21 Antigens,CR2 Receptors,Complement 3d Receptors,Complement Receptors 2,Epstein-Barr Virus Receptors,Receptors, C3d,Receptors, CR2,CD 21 Antigens,CD21 Antigen,Complement 3d Receptor,Complement Receptor 2,Epstein-Barr Virus Receptor,Herpesvirus 4 Receptors, Human,Receptors, Epstein-Barr Virus,Antigen, CD21,Antigens, CD 21,Epstein Barr Virus Receptor,Epstein Barr Virus Receptors,Receptor 2, Complement,Receptor, Complement 3d,Receptor, Epstein-Barr Virus,Receptors 2, Complement,Receptors, Epstein Barr Virus,Virus Receptor, Epstein-Barr,Virus Receptors, Epstein-Barr |
|